This study aimed to compare the efficacy of methylphenidate and atomoxetine on improving executive functions among children with attention-deficit/hyperactivity disorder (ADHD).
Methods:
This was an open-label, head-to-head, 3-month, randomized clinical trial with two-arm parallel-treatment groups: osmotic-release oral system methylphenidate (OROS-MPH; n = 79) and atomoxetine once daily (n = 78). Three major domains of executive functions were assessed, including response selection/inhibition, flexibility, and planning/working memory. The neuropsychological measures included the Conners' continuous performance test and the Cambridge Neuropsychological Test Automated Battery.
Results:
We found that both treatment groups showed improvement in executive functions (p-value <0.05 for the major indices of each domain). In addition, OROS-MPH was associated with a greater magnitude of improvement in the response selection/inhibition; the slope for detectability improvement in the Conners' continuous performance test was 0.06 for atomoxetine and 0.15 for OROS-MPH (p-value <0.01); the slope in rapid visual information processing was 2.22 for atomoxetine and 3.45 for OROS-MPH (p-value <0.05).
Conclusion:
Both OROS-MPH and atomoxetine improved various domains of executive functions in children with ADHD. There is greater improvement in response selection/inhibition among patients treated with OROS-MPH than those with atomoxetine. This trial was registered with ClinicalTrials.gov (no. NCT00916786).
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2.
Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology. CNS Drugs 23:33–41, 2009.
3.
ArnstenAF, LiB-M: Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biol Psychiatry, 57:1377–1384, 2005.
4.
BedardA-C, MartinussenR, IckowiczA, TannockR: Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 43:260–268, 2004.
5.
BédardACV, SteinMA, HalperinJM, KroneB, RajwanE, NewcornJH: Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry, 56:40–48, 2015.
6.
BymasterFP, KatnerJS, NelsonDL, Hemrick-LueckeSK, ThrelkeldPG, HeiligensteinJH, MorinSM, GehlertDR, PerryKW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27:699–711, 2002.
7.
ChiangHL, GauSS: Impact of executive functions on school and peer functions in youths with ADHD. Res Dev Disabil, 35:963–972, 2014.
8.
ChouT-L, ChiaS, ShangC-Y, GauSS-F: Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naive children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study. Eur Neuropsychopharmacol, 25:2300–2310, 2015.
9.
CoghillDR, SethS, PedrosoS, UsalaT, CurrieJ, GaglianoA: Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: Evidence from a systematic review and a meta-analysis. Biol Psychiatry, 76:603–615, 2014.
10.
ColletteF, Van der LindenM: Brain imaging of the central executive component of working memory. Neurosci Biobehav Rev, 26:105–125, 2002.
11.
CorteseS, D'AcuntoG, KonofalE, MasiG, VitielloB: New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Pharmacokinetics, efficacy, and tolerability. CNS Drugs 31:149–160.
12.
D'espositoM, PostleBR: The cognitive neuroscience of working memory. Annu Rev Psychol, 66:115–142, 2015.
13.
DiamondA. Executive functions. Annu Rev Psychol 64:135–168, 2013.
14.
DownesJ, RobertsA, SahakianB, EvendenJ, MorrisR, RobbinsT: Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychol, 27:1329–1343, 1989.
15.
EpsteinJN, ErkanliA, ConnersCK, KlaricJ, CostelloJE, AngoldA: Relations between continuous performance test performance measures and ADHD behaviors. J Abnorm Child Psychol, 31:543–554, 2003.
GauSS, ChenSJ, ChouWJ, ChengH, TangCS, ChangHL, TzangRF, WuYY, HuangYF, ChouMC, LiangHY, HsuYC, LuHH, HuangYS: National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry, 69:131–140, 2008.
18.
GauSS, HuangWL: Rapid visual information processing as a cognitive endophenotype of attention deficit hyperactivity disorder. Psychol Med, 44:435–446, 2014.
19.
GauSS, HuangYS, SoongWT, ChouMC, ChouWJ, ShangCY, TsengWL, AllenAJ, LeeP: A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 17:447–460, 2007.
20.
GauSS-F, LinC-H, HuF-C, ShangC-Y, SwansonJM, LiuY-C, LiuS-K: Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale-Teacher Form. J Pediatr Psychol, 34:850–861, 2008.
21.
GauSS, NiHC, ShangCY, SoongWT, WuYY, LinLY, ChiuYN: Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust N Z J Psychiatry, 44:135–143, 2010.
22.
GauSS, ShangCY: Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol, 13:243–256, 2010.
23.
GauSS, ShangCY: Executive functions as endophenotypes in ADHD: Evidence from the Cambridge Neuropsychological Test Battery (CANTAB). J Child Psychol Psychiatry, 51:838–849, 2010.
24.
GauSS, ShenHY, SoongWT, GauCS: An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol, 16:441–455, 2006.
25.
GauSS, TsengWL, TsengWY, WuYH, LoYC: Association between microstructural integrity of frontostriatal tracts and school functioning: ADHD symptoms and executive function as mediators. Psychol Med, 45:529–543, 2015.
26.
HannestadJ, GallezotJ-D, Planeta-WilsonB, LinS-F, WilliamsWA, van DyckCH, MalisonRT, CarsonRE, DingY-S: Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry, 68:854–860, 2010.
27.
HappéF, BoothR, CharltonR, HughesC. Executive function deficits in autism spectrum disorders and attention-deficit/hyperactivity disorder: Examining profiles across domains and ages. Brain Cogn, 61:25–39, 2006.
28.
HughesC, GrahamA: Measuring executive functions in childhood: Problems and solutions?. Child Adolesc Ment Health, 7:131–142, 2002.
29.
KonradK, GüntherT, HanischC, Herpertz-DahlmannB: Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 43:191–198, 2004.
30.
KratzO, StuderP, BaackJ, MalcherekS, ErbeK, MollGH, HeinrichH: Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: An event-related potential study using the attention network test. Prog Neuropsychopharmacol Biol Psychiatry, 37:81–89, 2012.
31.
LinYJ, ChenWJ, GauSS: Neuropsychological functions among adolescents with persistent, subsyndromal and remitted attention deficit hyperactivity disorder. Psychol Med, 27:1–13, 2013.
32.
LinY-J, GauSS-F: Developmental changes of neuropsychological functioning in individuals with and without childhood ADHD from early adolescence to young adulthood: A 7-year follow-up study. Psychol Med, 49:940–951, 2019.
33.
LogueSF, GouldTJ: The neural and genetic basis of executive function: Attention, cognitive flexibility, and response inhibition. Pharmacol Biochem Behav, 123:45–54, 2014.
34.
MehtaMA, GoodyerIM, SahakianBJ: Methylphenidate improves working memory and set-shifting in AD/HD: Relationships to baseline memory capacity. J Child Psychol Psychiatry, 45:293–305, 2004.
35.
MillerM, HinshawSP: Does childhood executive function predict adolescent functional outcomes in girls with ADHD?. J Abnorm Child Psychol, 38:315–326, 2010.
36.
NandamLS, HesterR, WagnerJ, CumminsTD, GarnerK, DeanAJ, KimBN, NathanPJ, MattingleyJB, BellgroveMA: Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biol Psychiatry, 69:902–904, 2011.
37.
NiHC, Hwang GuSL, LinHY, LinYJ, YangLK, HuangHC, GauSS: Atomoxetine could improve intra-individual variability in drug-naive adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. J Psychopharmacol, 30:459–467, 2016.
38.
NiHC, ShangCY, GauSS, LinYJ, HuangHC, YangLK: A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol, 16:1959–1973, 2013.
PievskyMA, McGrathRE: The neurocognitive profile of attention-deficit/hyperactivity disorder: A review of meta-analyses. Arch Clin Neuropsychol, 33:143–157, 2017.
41.
PolanczykG, De LimaMS, HortaBL, BiedermanJ, RohdeLA: The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry, 164:942–948, 2007.
42.
RhodesSM, CoghillDR, MatthewsK: Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II-broader executive and non-executive domains. J Child Psychol Psychiatry, 47:1184–1194, 2006.
43.
ShangC-Y, PanY-L, LinH-Y, HuangL-W, GauSS-F: An open-label, randomized trial of methylphenidate and atomoxetine treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 25:566–573, 2015.
44.
ShangCY, WuYH, GauSS, TsengWY: Disturbed microstructural integrity of the frontostriatal fiber pathways and executive dysfunction in children with attention deficit hyperactivity disorder. Psychol Med, 43:1093–1107, 2013.
45.
ShangCY, YanCG, LinHY, TsengWY, CastellanosFX, GauSS: Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med, 30:1–13, 2016.
SpencerT, BiedermanJ, WilensT: Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am, 9:77–97, 2000.
48.
StuhecM, LocatelliI: Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: A population-based study. Eur Psychiatry, 42:129–133, 2017.
49.
StuhecM, LukićP, LocatelliI: Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis. Ann Pharmacother, 53:121–133, 2019.
50.
TomasiD, VolkowND, WangG-J, WangR, TelangF, CaparelliEC, WongC, JayneM, FowlerJS: Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. Neuroimage, 54:3101–3110, 2011.
51.
TrippG, WickensJR: Neurobiology of ADHD. Neuropharmacology, 57:579–589, 2009.
52.
TsengWL, GauSS: Executive function as a mediator in the link between attention-deficit/hyperactivity disorder and social problems. J Child Psychol Psychiatry, 54:996–1004, 2013
53.
UnsworthN, RobisonMK: A locus coeruleus-norepinephrine account of individual differences in working memory capacity and attention control. Psychon Bull Rev, 24:1282–1311, 2017.
54.
WilensTE: Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol, 28:S46–S53, 2008.
55.
YangL, CaoQ, ShuaiL, LiH, ChanRC, WangY: Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: A randomized controlled trial. Int J Neuropsychopharmacol, 15:15–26, 2012.
56.
YildizO, SismanlarSG, MemikNC, KarakayaI, AgaogluB: Atomoxetine and methylphenidate treatment in children with ADHD: The efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev, 42:257–269, 2011.
57.
ZandbeltBB, VinkM: On the role of the striatum in response inhibition. PLoS One, 5:e13848, 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
